We are hiring! View our openings here ->

Making Transformative Medicine Accessible to Every Patient

Book A Demo

The Problem

Innovation Without Access Isn’t Impact

Drug innovators operate in the dark when it comes to real-world patient access. They invest billions each year to support access and uptake. Despite developing transformative therapies, the life sciences industry lacks visibility into the fragmented U.S. payer system, making it nearly impossible to understand — let alone fix — the barriers patients face in getting treated.

High-cost drugs approved by 2025
10-20
Price for a single treatment
$3.5M
Annual treatment spend by 2030
$25B+

Our Solution: AI Assistant for Drug Commercialization

Our AI assistant turns messy, unstructured healthcare data into clear, structured insights — giving drug innovators visibility and control over where patients are getting blocked. From high-level trends to pinpointing specific issues, we empower teams to act quickly, fix access barriers, reduce commercialization costs, and improve gross-to-net — all while maximizing impact.
Patients and Families
Transformative medicines are savings lives, but limited to those who can access them
Payers
New treatments pose challenges for payers who need to balance drug efficacy and limited budgets
Manufacturers
Getting payers to cover a new therapy is an time-intensive and frictional part of a treatment's go-to market process

Meet the Team

Our founding team is a group of healthcare experts, financial engineers, data scientists and leaders in industry.

Yutong Sun
Co-Founder & CEO
Former Lead Data Scientist, Oscar Health
Peter D. Hancock
Co-Founder
Former President and CEO, AIG and Former CFO, J.P. Morgan
Andrew W. Lo
Co-Founder
Charles E. and Susan T. Harris Professor of Finance at the MIT Sloan School of Management
Jonathan H. Gruber
Chief Policy Officer
Ford Professor of Economics at MIT

Our Advisors

Joel Klein
Former Assistant Attorney General of the United States
Sid Sankaran
Former Chairman and CEO, SiriusPoint
Mario Schlosser
Co-founder and Former CEO, Oscar Health
Alison Finger
Former Chief Commercial Officer, bluebird bio
Frank Zhang
Former Head of Commercial, Uniqure

Research

Quantile's insights on the social and economic impact of high-cost gene therapies

Read More